Provided by Tiger Fintech (Singapore) Pte. Ltd.

PainReform

1.91
+0.01000.53%
Post-market: 1.970.0600+3.14%19:01 EDT
Volume:17.30K
Turnover:32.94K
Market Cap:3.60M
PE:-0.06
High:1.93
Open:1.91
Low:1.89
Close:1.90
Loading ...

US Stocks Mixed; NY State Business Activity Rises In February

Benzinga
·
18 Feb

PainReform to Acquire AI-Driven Solar Analytics Platform DeepSolar From BladeRanger; Shares Up Pre-Bell

MT Newswires Live
·
18 Feb

PainReform Diversifies with Acquisition of AI Solar Platform DeepSolar

TIPRANKS
·
18 Feb

PainReform Executes Definitive Agreement to Acquire Deepsolar, Marking a Unique Expansion Opportunity

THOMSON REUTERS
·
18 Feb

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

GlobeNewswire
·
18 Feb

PainReform Ltd expected to post a loss of $18.96 a share - Earnings Preview

Reuters
·
07 Feb

PainReform Ltd expected to post a loss of $18.96 a share - Earnings Preview

Reuters
·
31 Jan

BRIEF-PainReform Provides Further Update On Phase 3 Clinical Trial Of PRF-110

Reuters
·
27 Dec 2024

PainReform Shares Down 18.4% After Pain Relief Treatment Fails to Meet Main Goal in Late Stage Trial

THOMSON REUTERS
·
27 Dec 2024

BUZZ-PainReform falls after pain relief treatment fails late-stage trial

Reuters
·
27 Dec 2024

PainReform Faces Setback in Phase 3 Trial for PRF-110

TIPRANKS
·
27 Dec 2024

PainReform Shares Down 24.9% Premarket After Pain Relief Treatment Fails to Meet Main Goal in Late Stage Trial

THOMSON REUTERS
·
27 Dec 2024

PainReform down 38% after resuming trading

TIPRANKS
·
27 Dec 2024

PainReform Ltd trading resumes

TIPRANKS
·
27 Dec 2024

PainReform Phase 3 trial on PRF-110 did not meet primary endpoint

TIPRANKS
·
27 Dec 2024

PainReform Provides Further Update on Phase 3 Clinical Trial of Prf-110

THOMSON REUTERS
·
27 Dec 2024

PainReform Ltd: Data From Final 24-Hour Period Did Not Meet Primary Endpoint of Study

THOMSON REUTERS
·
27 Dec 2024

PainReform Ltd - Initiates R&D Activities to Refine Pharmaco-Kinetics and Pharmaco-Dynamics of Prf-110

THOMSON REUTERS
·
27 Dec 2024

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

GlobeNewswire
·
27 Dec 2024

PainReform Shares Halted for News Pending Premarket

THOMSON REUTERS
·
27 Dec 2024